Is PYPD or AYTU more profitable?

PolyPid has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Aytu BioPharma -60.17% -69.93% -13.25%

Aytu BioPharma (AYTU) Competitors

$2.29 +0.01 (+0.44%)

As of 04:00 PM Eastern

Compare

AYTU vs. PYPD, CGTX, VRCA, FBIO, and ALDX

Should you buy Aytu BioPharma stock or one of its competitors? Aytu BioPharma's main competitors and comparable companies include PolyPid (PYPD), Cognition Therapeutics (CGTX), Verrica Pharmaceuticals (VRCA), Fortress Biotech (FBIO), and Aldeyra Therapeutics (ALDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aytu BioPharma compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, PolyPid had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for PolyPid and 0 mentions for Aytu BioPharma. PolyPid's average media sentiment score of 1.83 beat Aytu BioPharma's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Very Positive
Aytu BioPharma	Neutral

Aytu BioPharma has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 115.05%. Aytu BioPharma has a consensus price target of $10.75, suggesting a potential upside of 369.43%. Given Aytu BioPharma's higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

26.5% of PolyPid shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PolyPid has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

PolyPid beats Aytu BioPharma on 8 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cognition Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Cognition Therapeutics' return on equity of -50.17% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

In the previous week, Cognition Therapeutics had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for Aytu BioPharma. Cognition Therapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Cognition Therapeutics	Neutral
Aytu BioPharma	Neutral

Aytu BioPharma has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A

Cognition Therapeutics currently has a consensus target price of $3.33, suggesting a potential upside of 217.46%. Aytu BioPharma has a consensus target price of $10.75, suggesting a potential upside of 369.43%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cognition Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Summary

Cognition Therapeutics beats Aytu BioPharma on 9 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Aytu BioPharma (NASDAQ:AYTU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Aytu BioPharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A
Verrica Pharmaceuticals	$35.58M	2.59	-$17.89M	-$1.67	N/A

Aytu BioPharma has a net margin of -60.17% compared to Verrica Pharmaceuticals' net margin of -102.84%. Aytu BioPharma's return on equity of -69.93% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

Aytu BioPharma has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 1 mentions for Verrica Pharmaceuticals and 0 mentions for Aytu BioPharma. Verrica Pharmaceuticals' average media sentiment score of 0.20 beat Aytu BioPharma's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Verrica Pharmaceuticals	Neutral

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 369.43%. Verrica Pharmaceuticals has a consensus target price of $12.67, indicating a potential upside of 136.32%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Verrica Pharmaceuticals beats Aytu BioPharma on 9 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 527.31%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 369.43%. Given Fortress Biotech's higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 163.32% compared to Aytu BioPharma's net margin of -60.17%. Fortress Biotech's return on equity of 83.47% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Fortress Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

In the previous week, Fortress Biotech's average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Fortress Biotech	Neutral
Aytu BioPharma	Neutral

Fortress Biotech has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.43	$6.82M	$2.64	1.03
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A

Summary

Fortress Biotech beats Aytu BioPharma on 11 of the 12 factors compared between the two stocks.

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Aldeyra Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aldeyra Therapeutics' return on equity of -53.14% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

In the previous week, Aldeyra Therapeutics' average media sentiment score of 0.75 beat Aytu BioPharma's score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Aytu BioPharma	Neutral

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 271.62%. Aytu BioPharma has a consensus target price of $10.75, indicating a potential upside of 369.43%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aytu BioPharma has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A

Aldeyra Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Summary

Aldeyra Therapeutics and Aytu BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.47M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.50	787.27	273.28	25.38
Price / Sales	0.37	753.79	613.48	92.60
Price / Cash	6.07	94.80	77.82	52.26
Price / Book	1.09	12.33	12.89	6.14
Net Income	-$13.56M	$2.82B	$3.47B	$349.01M
7 Day Performance	2.23%	1.97%	-0.33%	-1.47%
1 Month Performance	1.78%	4.87%	6.51%	2.47%
1 Year Performance	-2.14%	9.15%	25.19%	15.84%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	2.0866 of 5 stars	$2.29 +0.4%	$10.75 +369.4%	-3.0%	$24.47M	$66.38M	N/A	160	Positive News
PYPD PolyPid	3.2373 of 5 stars	$5.33 +3.7%	$11.33 +112.6%	+55.4%	$98.09M	N/A	N/A	80	Positive News
CGTX Cognition Therapeutics	2.0235 of 5 stars	$1.01 -1.9%	$3.33 +230.0%	-56.8%	$97.95M	N/A	N/A	20	Positive News
VRCA Verrica Pharmaceuticals	3.9866 of 5 stars	$5.24 -4.0%	$12.67 +141.7%	+0.7%	$93.80M	$35.58M	N/A	40
FBIO Fortress Biotech	2.4374 of 5 stars	$2.68 -1.8%	$17.00 +534.3%	-8.4%	$91.21M	$63.26M	1.02	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. PYPD, CGTX, VRCA, FBIO, and ALDX

How does Aytu BioPharma compare to PolyPid?

Summary

How does Aytu BioPharma compare to Cognition Therapeutics?

Summary

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Summary

How does Aytu BioPharma compare to Fortress Biotech?

Summary

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. PYPD, CGTX, VRCA, FBIO, and ALDX

How does Aytu BioPharma compare to PolyPid?

Does the media favor PYPD or AYTU?

Which has better valuation and earnings, PYPD or AYTU?

Do analysts rate PYPD or AYTU?

Do insiders & institutionals hold more shares of PYPD or AYTU?

Which has more volatility and risk, PYPD or AYTU?

Is PYPD or AYTU more profitable?

Summary

How does Aytu BioPharma compare to Cognition Therapeutics?

Do insiders & institutionals believe in CGTX or AYTU?

Is CGTX or AYTU more profitable?

Does the media prefer CGTX or AYTU?

Which has higher valuation and earnings, CGTX or AYTU?

Do analysts rate CGTX or AYTU?

Which has more volatility and risk, CGTX or AYTU?

Summary

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Which has preferable valuation & earnings, AYTU or VRCA?

Is AYTU or VRCA more profitable?

Which has more volatility and risk, AYTU or VRCA?

Do institutionals & insiders have more ownership in AYTU or VRCA?

Does the media prefer AYTU or VRCA?

Do analysts prefer AYTU or VRCA?

Summary

How does Aytu BioPharma compare to Fortress Biotech?

Do insiders & institutionals have more ownership in FBIO or AYTU?

Do analysts rate FBIO or AYTU?

Is FBIO or AYTU more profitable?

Which has more volatility and risk, FBIO or AYTU?

Does the media favor FBIO or AYTU?

Which has better earnings & valuation, FBIO or AYTU?

Summary

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Is ALDX or AYTU more profitable?

Does the media favor ALDX or AYTU?

Do analysts recommend ALDX or AYTU?

Do insiders and institutionals have more ownership in ALDX or AYTU?

Which has higher valuation & earnings, ALDX or AYTU?

Which has more risk & volatility, ALDX or AYTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools